Belgian Diagnostic Device Detects Lung Cancer Mutations Where NGS Fails

Biocartis has shown its molecular diagnostic device could be used as an alternative to next generation sequencing to diagnose lung cancer patients.

Biocartis, a Belgian biotech, has shown that its Idylla EGFR Mutation Test, which detects mutations in the oncogene EGFR, can be used as an alternative to next generation sequencing (NGS). NGS could help identify treatments that would be most effective in particular patient populations, but it does not work in all patients. For example, DNA samples that are too small may not have enough DNA to give high-quality NGS results.

The current study looked at 68 DNA samples, of which 25 samples (37%) did not yield a valid result when analyzed using NGS. The samples were retested using the Idylla EGFR Mutation Test, which confirmed 100% of the valid NGS results. Furthermore, Idylla was able to analyze 20 out of the 25 samples that could not be assessed with NGS.

Four of the 20 samples were found to have actionable mutations for which a targeted treatment could be used. These results show that Biocartis’ test can benefit a larger population of patients with lung cancer — the leading cause of cancer deaths worldwide — with a test that delivers results in just around 2.5h.

Diagnostic devices could help improve patient survival by offering faster and more accurate diagnoses. Biocartis plans to launch the Idylla EGFR Mutation Test in the second half of 2018.

Image by Sebastian Kaulitzki/Shutterstock

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.